ADMA Biologics Provides Update on Global Intellectual Property Portfolio
December 09, 2021 07:00 ET
|
ADMA Biologics, Inc.
Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin Reinforces Existing and Pending IP that Provides for...
ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors
November 17, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC
November 16, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla. and MYRTLE BEACH, S.C., Nov. 16, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical...
ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
November 10, 2021 16:01 ET
|
ADMA Biologics, Inc.
Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020 Achieved First-Time Positive Gross Profit Narrowed Net Losses...
ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021
November 03, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 25, 2021 16:01 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and...
ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference
October 22, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock
October 21, 2021 09:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Proposed Public Offering of Common Stock
October 20, 2021 16:01 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 20, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization Conference
October 19, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...